Who are Gabapentin, Etoricoxib, Sugar pill's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gabapentin-etoricoxib-sugar-pill.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Gabapentin, Etoricoxib, Sugar pill — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gabapentin, Etoricoxib, Sugar pill (Gabapentin, Etoricoxib, Sugar pill) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination analgesic (gabapentinoid + selective COX-2 inhibitor + placebo). Area: Pain Management / Neurology.

marketed Combination analgesic (gabapentinoid + selective COX-2 inhibitor + placebo) Alpha-2-delta calcium channel subunit (gabapentin); COX-2 (etoricoxib) Pain Management / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Gabapentin, Etoricoxib, Sugar pill (Gabapentin, Etoricoxib, Sugar pill) — Meir Medical Center. This is a combination product containing gabapentin (a gabapentinoid that modulates calcium channels to reduce neuronal excitability), etoricoxib (a selective COX-2 inhibitor that reduces prostaglandin-mediated inflammation and pain), and a placebo control.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gabapentin, Etoricoxib, Sugar pill TARGET	Gabapentin, Etoricoxib, Sugar pill	Meir Medical Center	marketed	Combination analgesic (gabapentinoid + selective COX-2 inhibitor + placebo)	Alpha-2-delta calcium channel subunit (gabapentin); COX-2 (etoricoxib)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination analgesic (gabapentinoid + selective COX-2 inhibitor + placebo) class)

Meir Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gabapentin, Etoricoxib, Sugar pill — Competitive Intelligence Brief. https://druglandscape.com/ci/gabapentin-etoricoxib-sugar-pill. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab